undamentalytics Newsletter
Sign in

Cormedix Inc. insider trading

Every open-market purchase and sale by Cormedix Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $275,500 1 trade by 1 insider 3 months later: median −34.2% (−37.1% vs S&P 500) Insider sales, 5 years $2.6M 8 trades by 4 insiders 3 months later: median −38.5% (−38.5% vs S&P 500)
Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Cormedix Inc.’s insiders pay?

From December 16, 2013 to December 10, 2025, 19 insiders reported 66 open-market purchases and 24 sales not made under a pre-set plan in Cormedix Inc. Twelve months after each purchase was reported, the shares were −31.1% against the S&P 500 on average (median −35.0%), over 16 purchases with a full year of prices; 6% beat the index. After sales, the shares moved −52.1% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 26, 2019 into $4,963 by November 2, 2026, −8.8% a year. It held shares 86% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $26,543 (+13.7% a year), and held throughout $30,023 (+15.6%).

$0$10.0k$20.0k$30.0k 20192020202120222023202420252026 $30.0k$26.5k$5.0k
Copying Cormedix Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Cormedix Inc.'s insiders from March 26, 2019, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 86% of the time.
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Kaplan Myron Director 18 −34.9% (6) 0% 0 — October 27, 2025
Pfaffle Antony Interim Chief Medical Officer 0 — — 10 −55.0% (2) June 22, 2016
Lefkowitz Steven W Interim Chief Financial Ofcr 5 −22.8% (1) 0% 4 −62.0% (1) December 10, 2025
Dillione Janet Director 6 −54.0% (2) 0% 2 — November 26, 2025
Baluch Khoso Chief Executive Officer 7 −52.4% (1) 0% 0 — August 17, 2020
Todisco Joseph Chief Executive Officer 5 — — 1 −53.5% (1) September 12, 2025
Khan Mehmood Director 5 −10.5% (2) 0% 0 — August 20, 2020
Armstrong JR. John L. Exec VP of Tech Operations 4 −51.5% (2) 0% 0 — August 17, 2020
Tellez Cora M Director 4 — — 0 — May 17, 2017
Cook Robert W. Chief Financial Officer 3 — — 0 — November 27, 2018
Dunton Alan W Director 2 — — 1 −47.7% (1) September 16, 2025
Hurlburt Elizabeth Chief Operating Officer 0 — — 3 −44.3% (3) September 11, 2025
Duffy Matthew Director 0 — — 2 −58.5% (1) June 6, 2016
Markvicka Taunia Director 2 — — 0 — August 29, 2016
Mounts Phoebe General Counsel 2 −11.5% (1) 0% 0 — August 17, 2020
Gelbfish Gary A. Director 1 — — 0 — December 14, 2017
Milby Randy Chief Executive Officer 1 — — 0 — August 1, 2014
Mistry Erin EVP, Chief Commercial Officer 1 +30.6% (1) 100% 0 — December 13, 2024
Zelnick Kaufman Beth Chief Legal Officer 0 — — 1 −56.5% (1) September 11, 2025

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Cormedix Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Cormedix Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged −33.5% against the index. After 1 selling crowd, −38.6%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
September 30, 20254 selling+3.9%−38.6%−52.1%
January 31, 20202 buying−30.0%−32.5%+21.0%
August 30, 20192 buying−28.2%−34.5%−61.0%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Cormedix Inc. · Funds · Politicians